EUVIMEDEUVIMED entdecken
Crossref

Advanced stability-indicating RP-HPLC method for the quantification of lurasidone hydrochloride in bulk and PLGA-based in situ implant formulation

Bankar Anup Ramprasad, Sundeep Chaurasia, Indu Singh

Annales Pharmaceutiques Françaises · 2025

DOI: 10.1016/j.pharma.2024.10.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2025. Verfasst von Bankar Anup Ramprasad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, Uttar Pradesh 201301, India. Hauptthemen laut MEDLINE: Lurasidone Hydrochloride, Lactic Acid, Polyglycolic Acid, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Amity University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The aims of the present investigation was to develop and validate stability-indicating RP-HPLC method for the estimation of Lurasidone hydrochloride (LURA-H) followed by its drug product, LURA-H encapsulated poly-D,L lactic-glycolic acid (PLGA) based in situ depot forming implant (LURA-H-PLGA-ISI). METHODS: The LURA-H-PLGA-ISI formulation was developed by simple mixing method. According to international conference on harmonization guidelines, RP-HPLC method was developed and validated using Waters 2695 and discovery C18, 5μ, 250×4.6mm ID column. Force degradation studied were performed by various degradation techniques. RESULTS: The chromatographic separations of LURA-H as well as LURA-H-PLGA-ISI with good resolutions have been achieved using the mobile phase 0.1% orthophosphoric acid and acetonitrile (50:50). The linearity in the range of 25-150 μg/mL of developed method. LOD and LOQ limits for LURA-H were found to be 0.07μg/mL and 0.22μg/mL, respectively. The % RSD was found to be

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lurasidone HydrochlorideLactic AcidPolyglycolic AcidAntipsychotic AgentsChromatography, High Pressure LiquidPolylactic Acid-Polyglycolic Acid CopolymerDrug StabilityDrug ImplantsReproducibility of ResultsLimit of DetectionChromatography, Reverse-PhaseChemistry, Pharmaceutical

Stichwörter der Autor:innen

CLHPChlorhydrate de lurasidoneDégradation forcéeForce degradationImplant in situIn situ implantLurasidone hydrochlorideMéthode indicatrice de stabilitéPLGARP-HPLCStability-indicating method

Substanzen

Lurasidone HydrochloridePolylactic Acid-Polyglycolic Acid CopolymerLactic AcidDrug ImplantsPolyglycolic AcidAntipsychotic Agents

Autor:innen und Institutionen

  • Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, Uttar Pradesh 201301, India.
  • Ashland India Pvt. Ltd., Pharma R&D, Neovantage Innovation Parks, Building No. 2700, Hyderabad, Telangana 500078, India.
  • Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, Uttar Pradesh 201301, India. Electronic address: isingh5@amity.edu.

Förderung

  • Amity University

Zitieren

APA

Ramprasad, B. A., Chaurasia, S., & Singh, I. (2025). Advanced stability-indicating RP-HPLC method for the quantification of lurasidone hydrochloride in bulk and PLGA-based in situ implant formulation. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2024.10.008

Vancouver

Ramprasad BA, Chaurasia S, Singh I. Advanced stability-indicating RP-HPLC method for the quantification of lurasidone hydrochloride in bulk and PLGA-based in situ implant formulation. Annales Pharmaceutiques Françaises. 2025. doi:10.1016/j.pharma.2024.10.008

BibTeX
@article{Ramprasad2025,
  author = {Ramprasad, Bankar Anup and Chaurasia, Sundeep and Singh, Indu},
  title = {Advanced stability-indicating RP-HPLC method for the quantification of lurasidone hydrochloride in bulk and PLGA-based in situ implant formulation},
  journal = {Annales Pharmaceutiques Françaises},
  year = {2025},
  doi = {10.1016/j.pharma.2024.10.008}
}
Kostenlos starten →